Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu), a human FcRn-blocking ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The drug will be marketed under the brand name Imaavy.

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

As of 12:30:30 PM EDT. Market Open.

At close: April 28 at 4:00:01 PM EDT ...